MedTrace Logo

Medications After Adolescent Bariatric Surgery

NCT04572217 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-31

No results posted yet for this study

Summary

This study will assess the feasibility to assess practicality of early weight loss medication usage in adolescent patients post-VSG with inadequate weight loss. Participants who enroll in the study will be prescribed off-label use of weight loss medications for a period of up to 1 year.

Conditions

  • Pediatric Obesity

Interventions

DRUG

Topiramate

Topiramate (starting dose 25 mg daily, max dose 100 mg daily)

DRUG

Phentermine

Phentermine (starting dose 8 mg, max dose 16 mg)

Sponsors & Collaborators

  • Maternal and Child Health Research Institute

    collaborator UNKNOWN

  • Janey Pratt

    lead OTHER

Principal Investigators

  • Janey Pratt, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-06-01
Completion
2022-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04572217 on ClinicalTrials.gov